In relation to neurological disorders, PP2A has been suggested as a possible treatment target for neurological disorders Alzheimer’s disease (53) and has been recently implicated in Tau pathology of Parkinson’s disease (54). This evidence concerns the gene PTPA and nervous system disorder.